FDA Commissioner Marty Makary, MD, MPH, resigned Tuesday, according to The Associated Press, just 13 months after being ...
In today's ACT Brief, we examine cost models for imaging infrastructure in clinical trials, how community relationships ...
TransCelerate BioPharma has released a summary report from a joint tabletop exercise conducted with the FDA's Center for Drug ...
A phase 3 trial evaluating Moderna’s investigational seasonal influenza vaccine, mRNA-1010, found the messenger RNA ...
Week-24 TRuE-AD4 outcomes with ruxolitinib 1.5% cream showed 84.3% EASI75 and 70.6% IGA Treatment Success among completers ...
LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...
Guselkumab (Tremfya) showed higher 24-week fistula remission than placebo in adults with perianal fistulizing Crohn disease.
Aspenova randomizes Cyclin E1-positive PROC to azenosertib versus paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan, reflecting current nonplatinum standards in NCCN guidance.
Lastly, a broader view of clinical outcomes and operational insights is a cornerstone to product value translation. Gathering ...
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...
In a recent video interview with Applied Clinical Trials, Hal Green, senior solution architect and life sciences vertical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results